Tensions stemming from the U.S.-China trade war escalated sharply over the last few days, with much happening as Asian markets were shut down for the weekend.China Economyread more
The latest round of tariff announcements in the last few days means that by the end of the year, essentially all Chinese goods exported to the U.S. will be subject to duties.China Economyread more
Futures fell after Trump said the U.S. will raise tariffs on more than $500 billion worth of Chinese imports, increasing trade tensions.Marketsread more
Clouding the G-7 gathering, which represents the world's major industrial economies, are the tit-for-tat tariffs between Washington and Beijing.Politicsread more
Education Minister Ong Ye Kung says the Singapore government has been preparing for the challenge of an aging workforce "for the past 20 years."Employmentread more
World leaders, environmental groups and celebrities have publicly decried the vast swaths of forest being destroyed by the fires.World Newsread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
Hours after President Trump said Sunday he had "second thoughts" about escalating the trade war with China, the White House sought to explain his remark because it was...Politicsread more
President Donald Trump said that he would have a major trade deal with U.K. after it leaves the European Union.Politicsread more
Despite Kudlow's expectations, China said on Saturday that it strongly opposes Trump's decision to levy additional tariffs on $550 billion worth of Chinese goods, and warned...Politicsread more
President Donald Trump said Sunday he was not happy after North Korea launched short-range ballistic missiles over the weekend.Politicsread more
Bausch Health, formerly known as Valeant Pharmaceuticals, said Thursday that it and its dermatology business, Ortho Dermatologics, received approval from the Food and Drug Administration for its DUOBRII lotion to treat plaque psoriasis.
The company halted trading pending the news. Its shares rose more than 3% after trading resumed.
"With today's approval of DUOBRII, patients suffering from plaque psoriasis now have an innovative topical treatment option that uniquely combines two well-known ingredients, halobetasol propionate and tazarotene, with established safety profiles, into a single lotion featuring dual mechanisms of action," Bill Humphries, president of Ortho Dermatologics, said in a statement.
The lotion uses a "unique" combination of halobetasol propionate and tazarotene, which are topical treatments used to treat skin disorders such as itching and swelling.
Plaque psoriasis is a chronic skin disease that causes skin cells to rapidly build on the surface of the skin, creating dry, red lesions. About 7.5 million people in the United States live with psoriasis, with about 80% of them having plaque psoriasis.
Bausch conducted two clinical trials, with 36% of patients in the first study and 45% in the second study seeing their skin clear up. The company said a majority of the patients maintained success in a four-week post-treatment period, giving patients "clear" or "almost clear" skin. It said the lotion treated superficial reddening of the skin and reduced scaling on lesions caused by the disease in these patients.
Topical steroids are normally used to treat psoriasis, but some of these creams can cause the skin to thin, also known as epidermal atrophy.
Correction: This story previously stated that the DUOBRII lotion had received tentative approval from the FDA in October. It was actually Bausch Health's BRYHALI lotion for plaque psoriasis that received tentative approval.